Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is being made....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Delong, Zhao, Juanjuan, Song, Yongping, Luo, Xiaofeng, Yang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368716/
https://www.ncbi.nlm.nih.gov/pubmed/30736842
http://dx.doi.org/10.1186/s13045-019-0703-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368716/
https://www.ncbi.nlm.nih.gov/pubmed/30736842
http://dx.doi.org/10.1186/s13045-019-0703-z

Ejemplares similares